Campath-1H-Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy

doi:10.1056/NEJM200208083470619

Volume 347:452-453		August 8, 2002		Number 6

Campath-1H–Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

To the Editor: Treatment of chronic lymphocytic leukemia (CLL)with fludarabine results in a higher remission rate and longerprogression-free survival than do alkylating agents.¹ Patientswho have no response to fludarabine have a dismal prognosis,with a median survival of 10 months.² In these patients theanti–CD52 antibody alemtuzumab (Campath-1H, MabCampath)has recently shown promising results, with an overall responserate of 33 percent.³ The molecular mechanisms of its actionand the biologic factors associated with the clinical responseare not well defined.

A 72-year-old woman was given a diagnosis of CLL, Binet stageA, in August 1997. Because . . . [Full Text of this Article]

This article has been cited by other articles:

Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M., Dohner, H. (2009). Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. JCO 27: 3994-4001 [Abstract] [Full Text]
Tam, C. S., Shanafelt, T. D., Wierda, W. G., Abruzzo, L. V., Van Dyke, D. L., O'Brien, S., Ferrajoli, A., Lerner, S. A., Lynn, A., Kay, N. E., Keating, M. J. (2009). De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 114: 957-964 [Abstract] [Full Text]
Kipps, T. J. (2009). Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy. Am Soc Clin Oncol Ed Book 2009: 385-393 [Abstract] [Full Text]
Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H., Stilgenbauer, S. (2008). Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112: 3322-3329 [Abstract] [Full Text]
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., Kipps, T. J. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456 [Abstract] [Full Text]
Hewamana, S., Alghazal, S., Lin, T. T., Clement, M., Jenkins, C., Guzman, M. L., Jordan, C. T., Neelakantan, S., Crooks, P. A., Burnett, A. K., Pratt, G., Fegan, C., Rowntree, C., Brennan, P., Pepper, C. (2008). The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689 [Abstract] [Full Text]
Hauswirth, A. W., Jager, U. (2008). Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. haematol 93: 14-19 [Full Text]
Kipps, T. J. (2008). Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment. Am Soc Clin Oncol Ed Book 2008: 286-290 [Abstract] [Full Text]
Wierda, W. G. (2008). Treatments for Patients with Chronic Lymphocytic Leukemia. Am Soc Clin Oncol Ed Book 2008: 297-305 [Abstract] [Full Text]
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., Mayer, J. (2007). Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. JCO 25: 5616-5623 [Abstract] [Full Text]
Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., Nicot, C. (2006). Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108: 1021-1029 [Abstract] [Full Text]
Montserrat, E., Moreno, C., Esteve, J., Urbano-Ispizua, A., Gine, E., Bosch, F. (2006). How I treat refractory CLL. Blood 107: 1276-1283 [Abstract] [Full Text]
Wierda, W. G. (2006). Current and Investigational Therapies for Patients with CLL. ASH Education Book 2006: 285-294 [Abstract] [Full Text]
Ravandi, F., O'Brien, S. (2005). Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 80: 1660-1674 [Abstract]
Mone, A., Puhalla, S., Whitman, S., Baiocchi, R. A., Cruz, J., Vukosavljevic, T., Banks, A., Eisenbeis, C. F., Byrd, J. C., Caligiuri, M. A., Porcu, P. (2005). Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood 106: 3380-3382 [Abstract] [Full Text]
Wierda, W. G., Kipps, T. J., Keating, M. J. (2005). Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia. JCO 23: 6325-6332 [Abstract] [Full Text]
Hallek, M., On Behalf Of The German CLL Study Group, (2005). Chronic Lymphocytic Leukemia (CLL): First-Line Treatment. ASH Education Book 2005: 285-291 [Abstract] [Full Text]
Gribben, J. G. (2005). Salvage Therapy for CLL and the Role of Stem Cell Transplantation. ASH Education Book 2005: 292-298 [Abstract] [Full Text]
Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J., Waymer, S., Moran, M. E., Lucas, M. S., Farag, S. S., Byrd, J. C. (2005). FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105: 289-291 [Abstract] [Full Text]
Osuji, N., Del Giudice, I., Matutes, E., Dearden, C., Catovsky, D. (2004). Alemtuzumab for Chronic Lymphocytic Leukemia with and without p53 Deletions.. ASH ANNUAL MEETING ABSTRACTS 104: 2510-2510 [Abstract]
Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A., Arthur, D. C., Mitchell, J. B., Marti, G. E., Fowler, D. H., Wilson, W. H., Staudt, L. M. (2004). Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428-1434 [Abstract] [Full Text]
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., Proffitt, J. H., Lucas, D., Grever, M. R., Byrd, J. C. (2004). Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103: 3278-3281 [Abstract] [Full Text]
Byrd, J. C., Stilgenbauer, S., Flinn, I. W. (2004). Chronic Lymphocytic Leukemia. ASH Education Book 2004: 163-183 [Abstract] [Full Text]
Keating, M. J., Chiorazzi, N., Messmer, B., Damle, R. N., Allen, S. L., Rai, K. R., Ferrarini, M., Kipps, T. J. (2003). Biology and Treatment of Chronic Lymphocytic Leukemia. ASH Education Book 2003: 153-175 [Abstract] [Full Text]

Comments and questions? Please contact us.